Poolbeg Pharma CEO Jeremy Skillington and chairman Cathal Friel joined Proactive London to talk about making 'excellent progress post IPO as momentum builds'.
The results follow the company’s spin-out from Open Orphan PLC (AIM:ORPH, OTC:OPORF) and the subsequent listing on the AIM market of the London Stock Exchange in July 2021.
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a capital light clinical model which is looking to develop multiple products faster and more cost effectively than the conventional biotech model.